BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 28, 2015
 |  BioCentury  |  Finance

Deep pockets

Why Deciphera thinks the time was right to tap VC money

With four unpartnered cancer compounds in or entering the clinic, Deciphera Pharmaceuticals LLC decided it was finally time to raise venture money. Last week's $75 million series B round from a syndicate led by New Leaf Venture Partners should give the biotech enough runway to get to multiple data events.

"They've been successful moving molecules forward, and that causes capital needs to rise significantly. It was time to bring in others," said New...

Read the full 359 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >